Galectin Therapeutics Inc
F:PHPN
Galectin Therapeutics Inc
F:PHPN
Price:
3.02
EUR
2.72%
Market Closed
Market Cap:
€187.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
G
|
Galectin Therapeutics Inc
F:PHPN
|
US |
Balance Sheet
Balance Sheet Decomposition
Galectin Therapeutics Inc
Galectin Therapeutics Inc
Balance Sheet Decomposition is not available for
Galectin Therapeutics Inc
Galectin Therapeutics Inc
Balance Sheet
Galectin Therapeutics Inc
Galectin Therapeutics Inc
Currency: USD
| Dec-2002 | Dec-2003 | Dec-2004 | Dec-2005 | Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||||||
| Cash & Cash Equivalents |
2
|
8
|
11
|
4
|
1
|
1
|
0
|
0
|
6
|
6
|
9
|
10
|
29
|
26
|
15
|
3
|
8
|
47
|
27
|
40
|
19
|
26
|
15
|
18
|
|
| Cash Equivalents |
2
|
8
|
11
|
4
|
1
|
1
|
0
|
0
|
6
|
6
|
9
|
10
|
29
|
26
|
15
|
3
|
8
|
47
|
27
|
40
|
19
|
26
|
15
|
18
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
2
|
|
| Total Current Assets |
2
|
8
|
11
|
5
|
6
|
1
|
0
|
0
|
6
|
7
|
10
|
11
|
30
|
26
|
16
|
4
|
9
|
48
|
29
|
42
|
21
|
28
|
17
|
19
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Total Assets |
2
N/A
|
8
+251%
|
11
+39%
|
5
-55%
|
6
+28%
|
2
-72%
|
1
-61%
|
0
-37%
|
6
+1 332%
|
7
+5%
|
10
+45%
|
11
+12%
|
30
+177%
|
26
-11%
|
16
-40%
|
4
-74%
|
9
+117%
|
48
+438%
|
30
-39%
|
42
+41%
|
21
-49%
|
28
+32%
|
17
-38%
|
20
+12%
|
|
| Liabilities | |||||||||||||||||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
1
|
0
|
2
|
1
|
2
|
4
|
6
|
6
|
3
|
|
| Accrued Liabilities |
0
|
0
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
2
|
1
|
2
|
1
|
1
|
3
|
2
|
2
|
1
|
4
|
7
|
9
|
9
|
8
|
5
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
21
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Deferred Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
1
|
0
|
1
|
1
|
6
|
3
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
1
|
4
|
3
|
2
|
3
|
5
|
9
|
13
|
16
|
35
|
8
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
29
|
40
|
72
|
85
|
134
|
|
| Other Liabilities |
0
|
0
|
0
|
6
|
0
|
2
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
4
|
|
| Total Liabilities |
1
N/A
|
0
-43%
|
1
+166%
|
7
+625%
|
6
-13%
|
5
-26%
|
1
-75%
|
3
+156%
|
2
-40%
|
2
+25%
|
2
-26%
|
2
+52%
|
2
-32%
|
1
-20%
|
4
+178%
|
3
-21%
|
2
-29%
|
3
+36%
|
5
+89%
|
39
+625%
|
53
+36%
|
88
+65%
|
121
+36%
|
146
+21%
|
|
| Equity | |||||||||||||||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
7
|
7
|
7
|
7
|
7
|
8
|
9
|
9
|
9
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
|
| Retained Earnings |
8
|
13
|
20
|
23
|
26
|
35
|
39
|
48
|
56
|
69
|
80
|
102
|
119
|
140
|
164
|
181
|
196
|
216
|
240
|
271
|
310
|
354
|
402
|
433
|
|
| Additional Paid In Capital |
10
|
20
|
30
|
20
|
26
|
32
|
37
|
43
|
54
|
66
|
81
|
103
|
140
|
158
|
167
|
173
|
194
|
260
|
262
|
271
|
275
|
292
|
296
|
304
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
2
N/A
|
8
+370%
|
10
+33%
|
2
N/A
|
0
+99%
|
3
-14 500%
|
0
+84%
|
3
-443%
|
5
N/A
|
4
-3%
|
8
+80%
|
8
+4%
|
28
+240%
|
25
-10%
|
12
-52%
|
1
-90%
|
7
+480%
|
46
+561%
|
24
-47%
|
3
-89%
|
32
N/A
|
60
-87%
|
103
-71%
|
126
-22%
|
|
| Total Liabilities & Equity |
2
N/A
|
8
+251%
|
11
+39%
|
5
-55%
|
6
+28%
|
2
-72%
|
1
-61%
|
0
-37%
|
6
+1 332%
|
7
+5%
|
10
+45%
|
11
+12%
|
30
+177%
|
26
-11%
|
16
-40%
|
4
-74%
|
9
+117%
|
48
+438%
|
30
-39%
|
42
+41%
|
21
-49%
|
28
+32%
|
17
-38%
|
20
+12%
|
|
| Shares Outstanding | |||||||||||||||||||||||||
| Common Shares Outstanding |
3
|
4
|
5
|
5
|
5
|
7
|
8
|
9
|
11
|
13
|
16
|
18
|
22
|
29
|
33
|
36
|
41
|
57
|
57
|
59
|
59
|
62
|
63
|
65
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
4
|
5
|
5
|
5
|
4
|
4
|
4
|
7
|
7
|
7
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
Switch to:
Switch to:
Continue PHPN Research
Other Galectin Therapeutics Inc listings:
Discover More
